Copper-Catalyzed Benzylic C−H Oxygenation under an Oxygen Atmosphere via N-H Imines as an Intramolecular Directing Group
摘要:
Copper-catalyzed benzylic C-H oxygenation under an oxygen atmosphere was developed starting from carbonitriles and Grignard reagents via N-H imine intermediates. The present process is characterized by the following two-step sequence in a one-pot manner: (1) addition of Grignard reagents to carbonitriles to form N-H imines and (2) benzylic C-H oxygenation (C=O bond formation) triggered by 1,5-hydrogen atom transfer with transient iminyl copper species.
Methods of making compounds of the formula (I) wherein the variables are as defined herein. Also, methods of making compounds that may be used to inhibit dipeptidyl peptidase.
The present provides a condensed pyridine compound (I) represented by the following formula:
(wherein, R2 represents
ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and
B represents
its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.
[EN] DIPEPTIDYL PEPTIDASE INHIBITORS<br/>[FR] INHIBITEURS DE LA DIPEPTIDYLE PEPTIDASE
申请人:SYRRX INC
公开号:WO2005095381A1
公开(公告)日:2005-10-13
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising Formula (I): ##STR1## wherein M is N or CR4; Q1 and Q2 are each independently selected from the group consisting of CO, SO, SO2, and C=NR9; and each R1, R2, R3, R4 and R9 are as defined herein.
Certain 1,3-disubstituted isoquinoline derivatives
申请人:Eisai Co., Ltd.
公开号:US20040204421A1
公开(公告)日:2004-10-14
Condensed pyridine compounds represented by formula (I):
1
wherein: R
1
and R
3
are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R
2
represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.
The present provides a condensed pyridine compound (I) represented by the following formula:
1
ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and
B represents
2
its pharmaceutically acceptable salt or hydrates thereof, which isa clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.